Through their mechanism of action, the glucose-lowering effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) are modest.7 However, these drugs have recently received considerable attention in large cardiovascular safety trials owing to favorable HF and renal benefits. The gene discussed is SLC5A2; the disease is hydrops fetalis.